Brief: Landos Biopharma Inc - Landos Expects To Initiate Patient Dosing In First Half Of 2022
06/04/2021 12:35
April 6 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA ANNOUNCES FDA CLEARANCE OF IND
APPLICATION FOR
OMILANCOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS
* LANDOS BIOPHARMA INC - LANDOS EXPECTS TO INITIATE PATIENT
DOSING
IN FIRST HALF OF 2022
Source text for Eikon: ID:nGNX6sWX77
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma